pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

169 catalysts · 38 phase 2 completion · 28 phase 1 completion · 20 phase 1 2 completion · 17 phase 1 initiation · 15 phase 2 initiation · 12 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: multiple-sclerosis×TA: ophthalmology×TA: infectious-disease×TA: oncology×clear all
type
  • phase 2 completion38
  • phase 1 completion28
  • phase 1 2 completion20
  • phase 1 initiation17
  • phase 2 initiation15
phase 1 2 initiation
12
  • patent expiry7
  • phase 3 completion5
  • filing5
  • phase 0 trial completion4
  • therapy area
    • Oncology122
    • Infectious Disease36
    • Cardiology33
    • Immunology25
    • Dermatology21
    • Pulmonology16
    • Ophthalmology12
    • Women's Health11
    • Pain10

    Week of Apr 27, 2026

    50
    ›Apr 29, 2026phase 2 completion89d agoCARsgen Therapeutics Holdings Ltd — CT-0594CP CAR-T Cells (Phase II Trial Completion)CT-0594CP CAR-T Cells

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Plasma Cell Neoplasm, Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →CT-0594CP CAR-T Cells →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoMassachusetts Eye and Ear Infirmary — N-acetylcysteine (Phase II Trial Completion)N-acetylcysteine

    Therapy area: Ophthalmology. Indication: Cataract, Fuchs Endothelial Corneal Dystrophy (FECD)

    full page →N-acetylcysteine →source: globaldata
    ›Apr 29, 2026phase 2 completion89d agoSaraswati Dhanwantari Dental College and Hospital Parbhani — (amoxicillin + clavulanic acid) (Phase II Trial Completion)(amoxicillin + clavulanic acid)

    Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Periodontitis, Unspecified Infectious Diseases

    full page →(amoxicillin + clavulanic acid) →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoYunpeng Pharmaceutical Co Ltd — norfloxacin (Phase II Trial Initiation)norfloxacin

    Therapy area: Gastrointestinal, Genito Urinary System, Infectious Disease. Indication: Gonorrhea, Intestinal Infection, Salmonella Infections, Typhoid Fever, Urinary Tract Infections

    full page →norfloxacin →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)(daratumumab + hyaluronidase (human recombinant))

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma

    full page →(daratumumab + hyaluronidase (human recombinant)) →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoGoa Medical College — diclofenac (Phase II Trial Initiation)diclofenac ER

    Therapy area: Oncology, Toxicology. Indication: Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome), Colon Tumor

    full page →diclofenac ER →source: globaldata
    ›Apr 29, 2026phase 2 initiation89d agoHuahui Health Ltd — HH-006 (Phase II Trial Initiation)HH-006

    Therapy area: Infectious Disease. Indication: Hepatitis B

    full page →HH-006 →source: globaldata
    ›Apr 29, 2026phase 2 results89d agoSt. Vincent Health System — [177Lu]Lu-PSMA-597 (Phase II Trial Results)[177Lu]Lu-PSMA-597

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer

    full page →[177Lu]Lu-PSMA-597 →source: globaldata
    ›Apr 29, 2026phase 3 completion89d agoAstraZeneca Plc — durvalumab (Phase III Trial Completion)durvalumab

    Therapy area: Genito Urinary System, Oncology. Indication: Bladder Cancer, Bladder Carcinoma, Kidney Cancer (Renal Cell Cancer), Metastatic Transitional (Urothelial) Tract Cancer, Renal Stones/Calculi, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer

    full page →durvalumab →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase 3 initiation89d agoAll India Institute of Medical Sciences Bathinda — mitomycin (Phase III Trial Initiation)Jelmyto

    Therapy area: Ophthalmology. Indication: Open-Angle Glaucoma

    full page →Jelmyto →source: globaldata
    ›Apr 29, 2026phase iv trial initiation89d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe88d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026patent expiry88d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

    Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

    full page →isavuconazonium sulfate →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting88d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting88d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Wet (Neovascular / Exudative) Macular Degeneration

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Choroidal Neovascularization

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Retinal Vein Occlusion

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Retinopathy

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026filing88d agoXbrane Biopharma AB — ranibizumab biosimilar (NDA/BLA Filing (US))ranibizumab biosimilar

    Therapy area: Ophthalmology. Indication: Diabetic Macular Edema

    full page →ranibizumab biosimilar →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion88d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial initiation88d agoWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Brain Tumor

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoChugai Pharmaceutical Co Ltd — tocilizumab (Phase I Trial Completion)tocilizumab

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma

    full page →tocilizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoNational Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)Anti-CD19/CD20/CD22 CAR T-cells

    Therapy area: Oncology. Indication: Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), B-Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Lymphoma, Non-Hodgkin Lymphoma, Unspecified B-Cell Lymphomas

    full page →Anti-CD19/CD20/CD22 CAR T-cells →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

    Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

    full page →tegoprazan →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoEOC Pharma Ltd — EOC-237 (Phase I Trial Completion)EOC-237

    Therapy area: Oncology. Indication: Solid Tumor

    full page →EOC-237 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoIlife Consulting Sarl — PST-611 (Phase I Trial Completion)PST-611

    Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Dry (Atrophic) Macular Degeneration, Geographic Atrophy

    full page →PST-611 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoChangzhou Hengbang Pharmaceutical Co Ltd — risvutatug rezetecan (Phase I Trial Completion)risvutatug rezetecan

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →risvutatug rezetecan →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoNational Cancer Institute US — tuvusertib (Phase I Trial Completion)tuvusertib

    Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer

    full page →tuvusertib →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)cabozantinib s-malate

    Therapy area: Oncology. Indication: Solid Tumor

    full page →cabozantinib s-malate →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

    Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

    full page →MKK-900 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoCellenkos Inc — CK-0804 (Phase I Trial Completion)CK-0804

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)

    full page →CK-0804 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoBeOne Medicines AG — BG-89894 (Phase I Trial Completion)BG-89894

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor

    full page →BG-89894 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoAngel Pharmaceuticals Inc — soquelitinib (Phase I Trial Completion)soquelitinib

    Therapy area: Oncology. Indication: Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), T-Cell Leukemia, T-Cell Lymphomas

    full page →soquelitinib →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoKyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)brentuximab vedotin

    Therapy area: Oncology. Indication: Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

    full page →brentuximab vedotin →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoShanghai Institute of Biological Products Co Ltd — SIBPA-13 (Phase I Trial Completion)SIBPA-13

    Therapy area: Oncology. Indication: Breast Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Non-Small Cell Lung Cancer, Solid Tumor

    full page →SIBPA-13 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)stiripentol

    Therapy area: Oncology. Indication: Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer

    full page →stiripentol →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoNational Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)emavusertib hydrochloride

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    full page →emavusertib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoSiteman Cancer Center — soficabtagene geleucel (Phase I Trial Completion)soficabtagene geleucel

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sezary Syndrome, T-Cell Leukemia, T-Cell Lymphomas, Transformed Mycosis Fungoides

    full page →soficabtagene geleucel →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)daraxonrasib

    Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor

    full page →daraxonrasib →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

    Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

    full page →ciprofloxacin →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoOno Pharmaceutical Co Ltd — ONO-4578 (Phase I Trial Completion)ONO-4578

    Therapy area: Oncology. Indication: Breast Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →ONO-4578 →source: globaldata
    ›Apr 30, 2026phase 1 completion88d agoDaiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)raludotatug deruxtecan

    Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Ovarian Cancer, Renal Cell Carcinoma

    full page →raludotatug deruxtecan →source: globaldata
    ›Apr 30, 2026phase 1 initiation88d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ← prev
    page 2 of 4
    next →
    $AZN169.26+0.59%
    $INCY117.67+0.84%
    $CPIX6.6100-5.37%
    $AZN169.26+0.59%
    $AZN169.26+0.59%
    $TAK17.24+2.50%
    $ONC325.90-0.27%
    $RVMD189.23+0.25%